Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

302 INTERFERON BETA
(2004): Debat Zoguereh+, Rev Neurol (Paris) 160(11), 1081
Vesiculobullous eruption
Mucosal
Aphthous stomatitis
Balanitis
Cheilitis
Gingivitis
Glossitis
Mucosal bleeding (12–38%)
(1988): Sperber SJ+, JInfectDis158(1), 166 (12.5–38%)
Oral candidiasis
Sialorrhea
Tongue disorder (sic)
Vaginitis (4%)
Xerostomia
Hair
Hair – alopecia (4%)
Hair – hirsutism
Other
Anaphylactoid reactions/Anaphylaxis
(1999): Corona T+, Neurology 52(2), 425
Chills (21%)
(1998): Mohr DC+, Mult Scler 4(6), 487
Death
(2000): Beghi E+, Neurology 54(2), 469
Embolia cutis medicamentosa (Nicolau syndrome)
(2005): Reactions 1, 1058, 8
Fever
(2004): Festi D+, World J Gastroenterol 10(1), 12
(2002): Yang CH+, Chang Gung Med J 25(11), 774
(1999): Garcia-Moreno JM+, Neurologia 14(4), 154
(1998): Williams GJ+, JInterferonCytokine18(11), 967
(1997): Munschauer FE+, Clin Ther 19(5), 883
(1994): Connelly JF, Ann Pharmacother 28(5), 610
(1991): Allen J+, J Clin Oncol 9(5), 783
(1990): Fetell MR+, Cancer 65(1), 78
(1990): Von Hoff+, J Interferon Res 10(5), 531
(1990): Yung WK+, J Neurooncol 9(1), 29
(1987): Grunberg SM+, Cancer Res 47(4), 1174
(1987): Lillis PK+, Cancer Treat Rep 71(10), 965
(1986): Rinehart J+, Cancer Res 46(10), 5364
(1986): Sarna G+, Cancer Treat Rep 70(12), 1365
Fibrosis
(1997): Elgart GW+, JAmAcadDermatol37(4), 553
Graves’ disease
(2000): Rotondi M+, J Endocrinol Invest 23(5), 321
(1997): Schwid SR+, Arch Neurol 54(9), 1169
Hypersensitivity (3%)
Infections (11%)
Injection-site atrophy
Injection-site burning
Injection-site ecchymoses (2%)
Injection-site edema
(2004): Debat Zoguereh D+, Rev Neurol (Paris) 160(11), 1081
Injection-site erythema
(2004): Debat Zoguereh D+, Rev Neurol (Paris) 160(11), 1081
(1987): Grunberg SM+, Cancer Res 47(4), 1174
Injection-site hypersensitivity
Injection-site inflammation (3%)
Injection-site necrosis
(1999): Radziwill AJ+, J Neurol Neurosurg Psychiatry 67(1), 115
Injection-site pain
(2000): Gottberg K+, Mult Scler 6(5), 349
(1996): Mohr DC+, Mult Scler 2(5), 222
Injection-site panniculitis
(2002): Heinzerling L+, Eur J Dermatol 12(2), 194
Injection-site pruritus
(2004): Debat Zoguereh D+, Rev Neurol (Paris) 160(11), 1081
Injection-site purpura (2%)
Injection-site reactions (sic) (4%)
(2002): Panitch H+, Neurology 59(10), 1496
Injection-site ulceration
(2002): Yang CH+, Chang Gung Med J 25(11), 774
(1997): Elgart GW+, JAmAcadDermatol37(4), 553
(1997): Weinberg JM+, Acta Derm Venereol 77(2), 146
Lipoatrophy
(2006): Beiske AG+, JNeurol253(3), 377
Lipomatosis
Myalgia/Myositis/Myopathy/Myotoxicity (44%)
(2002): Yang CH+, Chang Gung Med J 25(11), 774
(1998): Williams GJ+, J Interferon Cytokine Res 18(11), 967
(1997): Munschauer FE+, Clin Ther 19(5), 883
(1994): Connelly JF, Ann Pharmacother 28(5), 610
(1988): Schiller JH+, J Interferon Res 8(5), 581
(1987): Grunberg SM+, Cancer Res 47(4), 1174
Nephrotoxicity
(2005): Auty A+, Can J Neurol Sci 32(3), 366
Pain (52%)
(2002): Heinzerling L+, Eur J Dermatol 12(2), 194 (52%)
Panniculitis
(2002): Heinzerling L+, Eur J Dermatol 12(2), 194
Peyronie’s disease
Rhabdomyolysis
(2002): Lunemann JD+, J Neurol Neurosurg Psychiatry 72(2), 274
Thrombophlebitis
(1999): Fortuno Y+, Med Clin (Barc) 113(12), 447 (2 cases)
(1997): Elgart GW+, JAmAcadDermatol37(4), 553
Upper respiratory infection (31%)
INTERLEUKIN-2
(See ALDESLEUKIN)
IODIXANOL
Trade name: Visipaque (Amersham Health)
Indications: Angiocardiography
Category: Iodine-containing radiocontrast medium
Half-life: 2 hours
Clinically important, potentially hazardous interactions
with: N/A
Reactions
Skin
Adverse effects (sic)
(2001): Sutton AG+, Am Heart J 141(4), 677
Edema (